Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Biopharmaceutics & Drug Disposition|March 24, 2021
When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populationsCaroline Sychterz, Aleksandra Galetin, Kunal S Taskar
Clinical Pharmacology and Therapeutics|November 13, 2025
Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug-Drug Interaction PredictionsKunal S Taskar, Pradeep Sharma, Karen Rowland Yeo
Current Drug Metabolism|January 5, 2021
Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug InteractionsKunal S Taskar, Isobel Harada, Ravindra V Alluri
CPT: Pharmacometrics & Systems Pharmacology|December 22, 2023
Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactionsGareth J Lewis, Deepak Ahire, Kunal S Taskar
Journal of Clinical Pharmacology|July 8, 2016
Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their MetabolitesMitesh Patel, Kunal S Taskar, Maciej J Zamek-Gliszczynski
CPT: Pharmacometrics & Systems Pharmacology|May 15, 2022
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidneyRyuta Asaumi, Ken-Ichi Nunoya, Yoshiyuki Yamaura, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 14, 2026
Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor NiraparibGareth J Lewis, Roxanne C Jewell, Anu Shilpa Krishnatry, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 1, 2023
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drugFarzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, et al.
Pharmaceutics|April 26, 2025
Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic ModelingHelen Tracey, Simon T Bate, Susan Ford, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 1, 2024
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancyFarzaneh Salem, Dung Nguyen, Mark Bush, et al.
Pageof 3